Serum lipoprotein Lp(a) in obesity

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Metabolic Syndrome

Background:

• Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD).
• Obesity is associated with increased CVD incidence.
• Limited data exist on Lp(a) concentrations in obese individuals with or without non-insulin-dependent diabetes mellitus (NIDDM).

Purpose of the Study:

• To investigate serum Lp(a) concentrations in obese men with normal glucose tolerance (NGT) and compare them to obese diabetic men, non-obese diabetic men, and healthy controls.
• To explore correlations between Lp(a) levels and metabolic parameters like glucose, insulin, BMI, and lipids.

Main Methods:

• Cross-sectional study involving four groups: obese NGT men (31), obese diabetic men (15), non-obese diabetic men (14), and healthy controls (17).
• Measurement of serum Lp(a), total cholesterol, HDL cholesterol, triglycerides, glucose, and insulin.
• Statistical analysis to compare Lp(a) levels and assess correlations.

Main Results:

• Mean Lp(a) levels were similar in obese NGT men (70.00 ± 13.40 mg/l) and controls (75.98 ± 24.70 mg/l).
• Significantly higher mean Lp(a) levels were observed in obese diabetic men (168.84 ± 56.43 mg/l) and non-obese diabetic men (240.85 ± 63.35 mg/l).
• A significant positive correlation was found between Lp(a) levels and glucose (P < 0.05), but not with age, BMI, or lipid profiles.

Conclusions:

• Hyperglycemia, a hallmark of NIDDM, may increase serum Lp(a) levels, potentially through hepatic glycosylation and reduced catabolic rate.
• Elevated Lp(a) in diabetic individuals, irrespective of obesity status, highlights the role of glycemic control in cardiovascular risk management.